From Minerals to Medicine

Salient is a Texas-based company formed in 2007 to explore the pharmaceutical application of its proprietary composition of a rare, all-natural mineral. This composition has been proven to adsorb a range of toxins and inflammatory proteins commonly associated with diarrhea.

Salient’s compound, CASAD™, is envisioned to be a “platform” product effective across a spectrum of conditions from Cancer Therapy-Induced Diarrhea to infectious disease and chronic GI conditions. It also has the potential to be used as a rescue agent for other drugs with toxic side effects.

Our Mission

Diarrhea is a debilitating problem for people on drug therapies dealing with a variety of infectious diseases or living with inflammatory GI diseases. In some situations, diarrhea can become life threatening. At Salient, our mission is improve patient health, the probability of therapy success and recovery rates by preventing and/or treating the diarrhea often associated with diseases and therapy regimens.

The Need for Salient’s CASAD™

Mild diarrhea is a frequent problem and is often treatable by a variety of inexpensive over-the-counter remedies.

Severe acute or chronic diarrhea, however, does not respond to simple treatments and is a debilitating problem for millions of people. It stems from a variety of causes including:

• Infectious diseases such as Clostridium difficile
• Therapeutic regimens for cancer and other illnesses
• Auto-immune conditions such as irritable bowel syndrome,Crohn’s disease or ulcerative colitis

In these situations, diarrhea may become life threatening, either as a primary cause or because patients can no longer tolerate treatment due to diarrheal side effects.

Product Development

With support from the National Cancer Institute (NCI), Salient is actively conducting a Phase II clinical trial to test the safety and efficacy of CASAD™. This trial is currently underway at M.D. Anderson Hospital and other sites with preliminary results expected in late 2010. In this first trial, Salient is testing the efficacy of its product to prevent and treat diarrhea associated with Irinotecan®, a common part of the treatment regimen for colorectal cancer.

Salient is also in the preliminary stages of testing CASAD™ in treating diarrhea associated with Clostridium difficile and inflammatory bowel disease.

Click here to get the latest clinical trial news.

Funding

Salient is a privately held C-corporation funded by a major academic institution and a group of private investors.

Click here for additional investor information.

Houston Technology Center Client

Salient is a client company of the Houston Technology Center (HTC), a business accelerator and the largest technology business incubator in Texas. HTC accelerates the commercialization of emerging technology companies in the Greater Houston area. A 501(C)(3)non-profit organization, HTC assists Houston-based entrepreneurs within several key sectors: Energy, Information Technology, Life Sciences, Nanotechnology and NASA/Aerospace technologies, by providing in-depth business guidance, access to capital and service providers, and entrepreneurial education.

For more information, visit www.houstontech.org.